




# PHARMACEUTICAL 2023

iBio Inc.  
Rank 225 of 446





# PHARMACEUTICAL 2023

iBio Inc.  
Rank 225 of 446



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 84% points. The greatest weakness of iBio Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 44% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	45,070
Cost of Goods Sold	216
Intangible Assets	4,851
Liabilities, Current	30,436
Liabilities, Non-Current	5,455
Other Assets	12,824
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	30
Other Net Income	-614
Other Revenues	2,383
Property and Equipment	36,661
Research and Development	17,729
Selling, General and Administrative Expense	34,128

Output Variable	Value in 1000 USD
Assets	99,406
Liabilities	35,921
Expenses	52,073
Revenues	2,383
Stockholders Equity	63,485
Net Income	-50,304
Comprehensive Net Income	-50,304
Economic Capital Ratio	87%